Unveiling the Layers of Nonclinical Dermal Studies

This week's Fierce Biotech is brought to you by Altasciences.

Trouble viewing? Click here.

In this issueof The Altascientist, we review the specific nonclinical requirements to move a dermal program forward to Phase I clinical trials and how to minimize inherent challenges—a case study using the minipig model is included.

READ THE ISSUE

Our experts have decades of experience supporting dermal drug development programs, from initial efficacy to clinical proof of concept. We boast one of North America's largest herds of miniature swine, including the most popular breeds of minipigs for dermal studies.

Speak with one of our experts today and let's get your program underway.

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

LET'S STAY CONNECTED!

YouTube

Blog

OUR SERVICES
Preclinical — Clinical — Manufacturing and Analytical
Bioanalysis — Research Support

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017